Vir Biotechnology
VIRPhase 3Vir Biotechnology is a public biotech company developing antibody-based therapies for infectious diseases and cancer. Its strategy is built on deep immunology expertise and two core technology platforms: a next-generation antibody platform for infectious diseases and the PRO-XTEN® protease-releasable masking technology for oncology. The company's most advanced program is in Phase 3 for chronic hepatitis delta, and it has demonstrated capability in rapidly advancing candidates, as seen with its COVID-19 and Ebola programs. Vir is led by an experienced management team and board with a track record of drug development and commercialization.
VIR · Stock Price
Historical price data
AI Company Overview
Vir Biotechnology is a public biotech company developing antibody-based therapies for infectious diseases and cancer. Its strategy is built on deep immunology expertise and two core technology platforms: a next-generation antibody platform for infectious diseases and the PRO-XTEN® protease-releasable masking technology for oncology. The company's most advanced program is in Phase 3 for chronic hepatitis delta, and it has demonstrated capability in rapidly advancing candidates, as seen with its COVID-19 and Ebola programs. Vir is led by an experienced management team and board with a track record of drug development and commercialization.
Technology Platform
Vir utilizes two core platforms: a next-generation antibody platform for infectious diseases to discover and engineer monoclonal antibodies, and the PRO-XTEN® protease-releasable masking technology to create conditionally activated therapeutics for oncology and infectious disease.
Pipeline Snapshot
2727 drugs in pipeline, 5 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| VIR-7831 + Placebo + Remdesivir | COVID-19 | Phase 3 |
| sotrovimab + sotrovimab + sotrovimab + sotrovimab + Sotrovimab + Sotrovimab + So... | Covid19 | Phase 3 |
| Tobevibart + Elebsiran + Bulevirtide | Viral Hepatitis | Phase 3 |
| Tobevibart + Elebsiran | Viral Hepatitis | Phase 3 |
| VIR-7831 (sotrovimab) + Placebo | Covid19 | Phase 2/3 |
Funding History
4Total raised: $993M
Opportunities
Risk Factors
Competitive Landscape
In hepatitis delta, Vir's main competitors are Gilead (approved in EU) and Eiger BioPharmaceuticals, though the landscape is sparse. Its antibody+masking technology platform competes with other modality-focused biotechs in immuno-oncology. Vir differentiates through its deep immunology expertise and a platform validated by prior regulatory successes in infectious disease.
Company Info
Trading
Therapeutic Areas
Partners
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile